Yanwen Jiang
Cornell University
H-index: 40
North America-United States
Top articles of Yanwen Jiang
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del (17p) chronic lymphocytic leukemia | Blood Advances | Stephan Stilgenbauer Eugen Tausch Andrew W Roberts Matthew S Davids Barbara Eichhorst | 2024/2/1 |
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) | Hematological Oncology | AP Kater R Harrup TJ Kipps B Eichhorst CJ Owen | 2023/6 |
Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study | American journal of hematology | Elisabeth A Lasater Dhara N Amin Rajat Bannerji Raghuveer Singh Mali Kathy Barrett | 2023/3 |
Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study | Blood | Fabrice Jardin Vibha Raghavan Samuel Tracy Sandhya Balasubramanian Laurie H Sehn | 2023/11/28 |
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic … | nature communications | Othman Al-Sawaf Can Zhang Hyun Yong Jin Sandra Robrecht Yoonha Choi | 2023 |
Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study. | Alex Francisco Herrera Samuel Tracy Laurie Helen Sehn Fabrice Jardin Georg Lenz | 2023/6/1 | |
Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including … | Blood | Andrew D Zelenetz Catherine S Diefenbach Charles Herbaux Monica Tani Roch Houot | 2023/11/28 |
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial | Blood | Yuqin Song Hervé Tilly Shinya Rai Huilai Zhang Jie Jin | 2023/4/20 |
S201: Final 7-year follow up and retreatment substudy analysis of murano: venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R … | HemaSphere | Arnon Kater Rosemary Harrup Thomas J Kipps Barbara Eichhorst Carolyn J Owen | 2023/8/1 |
Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study | Blood | Franck Morschhauser Wilfred Leung Vibha Raghavan Georg Lenz Fabrice Jardin | 2023/11/28 |
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia | Nature Communications | Othman Al-Sawaf Can Zhang Hyun Yong Jin Sandra Robrecht Yoonha Choi | 2023/4/18 |
IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY | Hematological Oncology | F Morschhauser K Hatzi G Lenz AF Herrera CR Flowers | 2023/6 |
Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia … | Blood | Rosemary Anne Harrup Arnon P Kater Barbara F Eichhorst Carolyn Owen Brenda Chyla | 2023/11/28 |
Preclinical evaluation of mosunetuzumab for the treatment of relapsed/refractory chronic lymphocytic leukemia | Cancer Research | Kathy Barrett Kai Lu Hyun Yong Jin Rosie Millen Marcus Lefebure | 2023/4/4 |
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY | Hematological Oncology | O Al‐Sawaf S Robrecht C Zhang S Olivieri YM Chang | 2023/6 |
Identification of MYC-Driven High-Grade B-Cell Lymphoma Using Deep Learning-Based Whole Slide Image Analysis | Blood | Anil Yüce Christian Doerig Jacob Gildenblat Samaneh Abbasi-Sureshjani Agata Mosinska | 2023/11/28 |
CLL-246 venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study | Clinical Lymphoma Myeloma and Leukemia | Othman Al-Sawaf Can Zhang Sandra Robrecht Alex Kotak Naomi Chang | 2022/10/1 |
Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and … | Oncology Research and Treatment | Sascha Dietrich Herve Tilly Franck Morschhauser Laurie H Sehn Jonathan W Friedberg | 2022 |
S148: Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized cll14 study | HemaSphere | Othman Al-Sawaf Can Zhang Sandra Robrecht Alex Kotak Naomi Chang | 2022/6/1 |
ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and … | Clinical Lymphoma Myeloma and Leukemia | Christopher Flowers Hervé Tilly Franck Morschhauser Laurie H Sehn Jonathan W Friedberg | 2022/10/1 |
